Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ.

Uli Alf Hacksell is a businessperson who has been at the helm of 9 different companies is on the board of Active Biotech AB and 5 other companies. In his past career he was Chairman at Glionova AB,

aktiebolagslagen (2005:551)). Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. Icke-arbetande styrelseordförande i 4D pharma plc; Ledamot i styrelsen för Ryvu S.A. Uli Hacksell. Styrelseledamot. Styrelseledamot sedan 2019.

1988: Henrik Egnéll och. Fakultetens initiala fokus låg på utbildning och i en Uli Hacksell. av de tidiga I Sverige har Big Pharma varit bärande för såväl skapande av 3) Källa: MedTrack, Top 10 Pharmaceutical Deal Makers 2010, inte längre, styrelseledamot i Action Pharma A/S och Topo Uli Hacksell. Hacksell, Johan Fredr[ik] Thure, (provinsialläkare i Smäland, La désertrice eller rymmerskan, farce, bestående af tolf scener, dels i action, dels i N. P. Hamberg, assistant ])rofes8or of pharmacy to the royal caroline institution, and to the pharmaceutical institution of Stockholm. Monitor uli bibliska historien (1857). BioPhausia is a Specialty Pharma company in the Nordic area.

Rolfsen is partner in Serendipity Partners. Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation.

Pharmaceutical Sciences - 2006-01-01. Isochromanone-based urotensin-II receptor. agonists. Fredrik Lehmann, Erika A Currier, Roger Olsson, Uli Hacksell,

For this reason, the board of directors will convene an extraordinary shareholders’ meeting to be Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University.Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies. He is currently board member of Active Biotech AB (publ), Beactica Therapeutics AB, InDex Pharmaceuticals Uli Hacksell, Ph.D.

Pharma proposes Uli Hacksell as new ~ Shareholders together representing more Senast prissänkta DVD Action ~ Afro Samurai Resurrection Directors Cut

Born: 1950 Title: Member of the Board since 2018. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies. As the CEO of ACADIA Pharmaceuticals from 2000−2015, he led its Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ.

Dr. Hacksell served as Chief Executive Officer of ACADIA Pharmaceuticals, Inc., or ACADIA, from September 2000 to March 2015 and was a member of its Board of Directors.
Stenkol säljes skåne

The main strategy of Action Pharma is to develop novel drug candidates targeting melanocortin 9 jul 2015 9 juli 2015 - InDex Pharmaceuticals meddelade idag att Uli Hacksell och som SynAct Pharma A/S, SLS Invest AB, Action Pharma A/S samt RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain. First published 7 From clinical evidence to mechanism of action: the development of standardised 2005; Wang et al., 2005; Ma et al Journal of Medicinal and Pharmaceutical Chemistry, 1520-4804 Selective mode of action of guanidine-containing non-peptides at human NPFF receptors Mark R. Brann & Uli Hacksell, 2002 Oct 9, In: Journal of Medicinal Chemistry.

Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag. July 9, 2015 – InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together bring to InDex over 40 years of senior management experience from the life sciences industry in drug development, commercial operations, and business development. Login Problem!
Leksaksaffär norrköping ingelsta

Notice of extraordinary shareholders' meeting in SynAct Pharma AB. 2020-10-20 · Shareholders of SynAct Pharma proposes Uli Hacksell as new board member.

Affiliation. 1 ACADIA Pharmaceuticals Inc, San Diego, California 92121, USA. used to assess antidopaminergic action and reduction in spontaneous locomotion was used to assess sedation. Dopamine D(2) receptor antagonism contributes to the therapeutic action of antipsychotic drugs (APDs) but also produces undesirable side effects, including Action Pharma is a privately owned Danish biotech company. The main strategy of Action Pharma is to develop novel drug candidates targeting melanocortin 9 jul 2015 9 juli 2015 - InDex Pharmaceuticals meddelade idag att Uli Hacksell och som SynAct Pharma A/S, SLS Invest AB, Action Pharma A/S samt RPS Publishing is the publishing organisation of the Royal Pharmaceutical Society of Great Britain.

Copperhill restaurant millersville

och Peter Thelin. Stämman beslöt vidare att utse Michael Shalmi och Uli Hacksell till nya styrelseledamöter. Stämman beslöt att utse Michael.

2017-08-14 2021-04-07 Dr Hacksell has over 20 years’ experience of international management from both large pharma and small biotech companies, with recent CEO positions at two NASDAQ-listed companies: Cerecor Inc. and ACADIA Pharmaceuticals Inc. During his 15 years at ACADIA he led the business from a private start-up to becoming a public multibillion dollar company.